Citius Oncology (CTOR) Payables (2023 - 2026)

Citius Oncology's Payables history runs 4 years deep, the most recent figure standing at $6.0 million for Q1 2026.

• In Q1 2026, Payables fell 47.72% year-over-year to $6.0 million; the TTM figure through Mar 2026 stood at $6.0 million (down 47.72% YoY), while the FY2025 annual figure was $17.0 million, up 126.78% from the prior year.
• Payables was $6.0 million for Q1 2026 at Citius Oncology, down from $14.2 million in the prior quarter.
• In the past five years, Payables ranged from a high of $17.0 million in Q3 2025 to a low of $1.3 million in Q3 2023.
• Historically, Payables has averaged $7.7 million across 4 years, with a median of $7.5 million in 2024.
• The sharpest annual moves came in 2025 and 2026: Payables surged 655.03% in 2025, then tumbled 47.72% in 2026.
• A 4-year view of Payables shows it stood at $1.3 million in 2023, then surged by 632.93% to $9.7 million in 2024, then jumped by 47.26% to $14.2 million in 2025, then plunged by 57.89% to $6.0 million in 2026.
• The last three Payables figures came in at $6.0 million (Q1 2026), $14.2 million (Q4 2025), and $17.0 million (Q3 2025), per Business Quant data.